Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. (September 2021)

• Record Type: Journal Article
• Authors: Denda, Tadamichi; Takashima, Atsuo; Gamoh, Makio; Iwanaga, Ichiro; Komatsu, Yoshito; Takahashi, Masanobu; Nakamura, Masato; Ohori, Hisatsugu; Sakashita, Akiko; Tsuda, Masahiro; Kobayashi, Yoshimitsu; Baba, Hideo; Kotake, Masanori; Ishioka, Chikashi; Yamada, Yasuhide; Sato, Atsushi; Yuki, Satoshi; Morita, Satoshi; Takahashi, Shin; Yamaguchi, Tatsuro; Shimada, Ken
• Is Part Of: European journal of cancer. Volume 154(2021)
• Page Start: 296
• Page End: 306
• Publication Date: 2021-09
• Subjects: IRIS -- SIRB -- FOLFOX -- XELOX -- Sidedness; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2021.06.013
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Aim: The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC). Overall survival (OS) data were immature at the time of the primary analysis. Methods: In total, 487 patients from 53 institutions with previously untreated mCRC were randomly assigned (1:1) to receive either mFOLFOX6/CapeOX plus bevacizumab (control group) or S-1 and irinotecan plus bevacizumab (experimental group; 3- or 4-week regimen). The final OS data were analysed from follow-up data collected until 30th September 2017. Results: With a median follow-up period of 48.7 months, median survival times were 32.6 and 34.3 months (hazard ratio [HR]: 0.89, 95% confidence interval [CI]: 0.72–1.10, P = 0.293) and median PFS durations were 10.8 and 14.0 months in the control and experimental groups, respectively (HR: 0.86, 95% CI: 0.71–1.04, P < 0.0001 for non-inferiority). In patients with left-sided RAS wild-type tumours, median PFS durations were 11.4 and 16.9 months in the control and experimental groups, respectively (HR: 0.68, 95% CI: 0.48–0.96, P = 0.028). Conclusion: S-1 and irinotecan plus bevacizumab resulted in comparable OS and non-inferior PFS with that of mFOLFOX6/CapeOX plus bevacizumab treatment as first-line chemotherapy for patients with mCRC. We recommend the use of S-1 and irinotecan plus bevacizumab as a standard first-line regimen independent of tumour sidedness or RAS status in mCRC. Trial registration: UMIN-CTR: 000007834. Highlights: S-1/irinotecan/bevacizumab had survival comparable with that of standard therapy. QOL for neurotoxicity showed a favourable trend in the S-1/irinotecan/bevacizumab. S-1/irinotecan/bevacizumab had efficacy, regardless of RAS and tumour location.